Dyax Investor Slams Shire's $5.9B Offer As Too Low
A Dyax Corp. investor on Tuesday launched a putative class action in Delaware Chancery Court challenging the biopharma company's $5.9 billion merger pact with U.K.-based drugmaker Shire PLC, saying company directors...To view the full article, register now.
Already a subscriber? Click here to view full article